Spot BPDCN fast: skin-first clues, CD123/CD4/CD56 triad, mandatory CNS staging, and transplant-focused remission strategy.
The BPDCN Revolution: Navigating the New Era of Targeted Therapy
BPDCN breakthroughs: CD123-targeting tagraxofusp and venetoclax-azacitidine combinations boost remissions, limit myelosuppression, and help reach transplant.
In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, outlines monitoring parameters and intervention strategies required for patient safety following treatment with tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores the clinical rationale for triplet regimens combining tagraxofusp-erzs (Elzonris), azacitidine (Vidaza), and ventoclax (Venclexta).
In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.
In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, discusses the future of BPCDN treatment and how a collaborative care model should play a role in this rare disease.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Selecting Between IO/TKI and IO/IO Combination Therapy
2
After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC
3
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma
4
Real-World Tolerability of Cilta-Cel Aligns With Multiple Myeloma Trials
5